These results support the concept of targeting DOCK family GEFs, particularly DOCK2, as part of a co-inhibition strategy to suppress RAC1P29S-driven signaling, reducing melanoma progression, invasion, and resistance to BRAF inhibitors. The gene discussed is BRAF; the disease is melanoma.